BioDelivery Sciences International Inc. (NASDAQ:BDSI)’s share price fell 2.3% on Monday . The stock traded as low as $2.50 and last traded at $2.52, with a volume of 233,882 shares trading hands. The stock had previously closed at $2.58.

Several research firms have weighed in on BDSI. Cantor Fitzgerald restated a “hold” rating on shares of BioDelivery Sciences International in a report on Saturday. FBR & Co raised their target price on BioDelivery Sciences International from $9.00 to $12.00 and gave the company an “outperform” rating in a report on Wednesday, May 4th. Zacks Investment Research lowered BioDelivery Sciences International from a “buy” rating to a “hold” rating in a report on Tuesday. Janney Montgomery Scott restated a “hold” rating on shares of BioDelivery Sciences International in a report on Tuesday. Finally, Piper Jaffray Cos. restated an “overweight” rating and set a $4.00 target price (down from $6.00) on shares of BioDelivery Sciences International in a report on Thursday, May 12th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $8.38.

The firm’s market cap is $136.66 million. The stock’s 50 day moving average is $2.40 and its 200 day moving average is $3.23.

BioDelivery Sciences International (NASDAQ:BDSI) last announced its earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.36) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.35) by $0.01. The company had revenue of $3 million for the quarter, compared to analysts’ expectations of $2.96 million. During the same period in the previous year, the firm posted ($0.16) earnings per share. The company’s revenue for the quarter was down 77.1% on a year-over-year basis. On average, analysts predict that BioDelivery Sciences International Inc. will post ($1.19) EPS for the current year.

A number of institutional investors recently made changes to their positions in BDSI. Royce & Associates LLC raised its position in shares of BioDelivery Sciences International by 6.2% in the fourth quarter. Royce & Associates LLC now owns 1,487,800 shares of the specialty pharmaceutical company’s stock worth $7,127,000 after buying an additional 87,200 shares during the last quarter. Russell Frank Co raised its position in shares of BioDelivery Sciences International by 57.5% in the fourth quarter. Russell Frank Co now owns 1,080,051 shares of the specialty pharmaceutical company’s stock worth $5,151,000 after buying an additional 394,272 shares during the last quarter. Turner Investments L.P. raised its position in shares of BioDelivery Sciences International by 55.4% in the fourth quarter. Turner Investments L.P. now owns 900,830 shares of the specialty pharmaceutical company’s stock worth $4,315,000 after buying an additional 321,290 shares during the last quarter. Bank of Montreal Can raised its position in shares of BioDelivery Sciences International by 3.6% in the fourth quarter. Bank of Montreal Can now owns 829,056 shares of the specialty pharmaceutical company’s stock worth $3,971,000 after buying an additional 28,838 shares during the last quarter. Finally, 1492 Capital Management LLC raised its position in shares of BioDelivery Sciences International by 8.3% in the fourth quarter. 1492 Capital Management LLC now owns 538,538 shares of the specialty pharmaceutical company’s stock worth $2,580,000 after buying an additional 41,069 shares during the last quarter.

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.